Abuse-resistant mucoadhesive devices for delivery of buprenorphine

The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.

MEDICAL OR VETERINARY SCIENCE; HYGIENE

Drugs for disorders of the alimentary tract or the digestive system

SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite-containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides-Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 

Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite-Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Inorganic compounds

Medicinal preparations characterised by special physical form -Web, sheet or filament bases ; ; Films; Fibres of the matrix type containing drug -Drug-containing films, membranes or sheets 

Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Drugs for disorders of the nervous system

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite-containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides-Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Medicinal preparations containing organic active ingredients-Heterocyclic compounds-having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins-having six-membered rings with one nitrogen as the only ring hetero atom-Quinolines; Isoquinolines-Morphinan derivatives, e.g. morphine, codeine

Drugs for disorders of the nervous system-for treating abuse or dependence-Opioid-abuse

Drugs for disorders of the nervous system-Centrally acting analgesics, e.g. opioids

Medicinal preparations containing organic active ingredients-Heterocyclic compounds-having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins-having six-membered rings with one nitrogen as the only ring hetero atom-8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite-containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides-Carboxylic acids; Salts or anhydrides thereof

Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates-Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers ; , poly(meth)acrylates, or polyvinyl pyrrolidone

Medicinal preparations characterised by special physical form -Galenical forms characterised by the site of application-Mouth and digestive tract, i.e. intraoral and peroral administration -Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates-Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin-Cellulose; Derivatives thereof

Medicinal preparations containing organic active ingredients-Heterocyclic compounds-having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins-having six-membered rings with one nitrogen as the only ring hetero atom-Quinolines; Isoquinolines-forming part of bridged ring systems 

General protective or antinoxious agents-Antidotes

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

General

Analytics

Cases

Patent Assignments

Citations